Meningococcal B Vaccine Indications
Routine Vaccination
- The American College of Physicians and the Centers for Disease Control and Prevention recommend MenB vaccine for persons aged ≥10 years at increased risk for serogroup B meningococcal disease, with a Category A recommendation 1, 2
- The American Academy of Pediatrics recommends MenB vaccine for persons with anatomical or functional asplenia, including sickle cell disease, due to a 40-70% case fatality rate from meningococcal disease 3, 4
- The American College of Physicians recommends MenB vaccine for persons with persistent complement component deficiencies, including inherited or chronic deficiencies of C3, C5-C9, properdin, factor D, or factor H 1, 5, 6
- The Centers for Disease Control and Prevention recommend MenB vaccine for persons receiving eculizumab, a complement inhibitor therapy 3, 1
- The American College of Physicians and the Centers for Disease Control and Prevention recommend MenB vaccine for microbiologists routinely exposed to isolates of Neisseria meningitidis 1, 5, 6
- The Centers for Disease Control and Prevention recommend MenB vaccine for persons at risk during a serogroup B meningococcal disease outbreak 1, 7, 6
Shared Clinical Decision-Making
- The American Academy of Pediatrics and the Centers for Disease Control and Prevention recommend considering MenB vaccine for healthy adolescents and young adults aged 16-23 years, with a preferred age of 16-18 years, based on individual clinical decision-making 3, 4, 2
- The American Academy of Pediatrics notes that approximately 50-60 cases of serogroup B disease occur annually in adolescents and young adults aged 11-24 years in the United States 3, 4
- The American Academy of Pediatrics states that college students have a lower risk of serogroup B disease than the general population of similar age 3, 4
Vaccine Dosing Schedules
- The Centers for Disease Control and Prevention recommend a 3-dose series of MenB-FHbp (Trumenba) at 0, 1-2, and 6 months for high-risk persons aged ≥10 years 2, 8
- The Centers for Disease Control and Prevention recommend a 2-dose series of MenB-FHbp (Trumenba) at 0 and 6 months for healthy adolescents aged 16-23 years 2
Booster Doses
- The Centers for Disease Control and Prevention recommend a booster dose of MenB vaccine for persons at continued increased risk if ≥1 year has elapsed since completion of the primary series 7, 2, 8
Important Caveats and Pitfalls
- The American College of Physicians and the Centers for Disease Control and Prevention note that MenB vaccines are FDA-licensed for ages 10-25 years, but may be used off-label in persons ≥26 years at increased risk 1, 6, 2
- The American Academy of Pediatrics and the Centers for Disease Control and Prevention state that MenB vaccine is not recommended for travel to hyperendemic or epidemic areas, as disease in these regions is generally not caused by serogroup B 3, 1, 4, 6
- The American Academy of Pediatrics notes that MenB vaccine is not recommended for military recruits or for HIV infection alone 3, 4, 1, 6
- The Centers for Disease Control and Prevention recommend deferring MenB vaccination during pregnancy unless the woman is at increased risk, in which case benefits should be weighed against potential risks 2, 8
- The American College of Physicians and the Centers for Disease Control and Prevention recommend administering MenB vaccines simultaneously with MenACWY vaccine but at a different anatomical site 1, 6, 2
CDC Guidelines for Penbraya (MenACWY‑TT/MenB‑FHbp) Vaccination in Patients Receiving Upadacitinib (Rinvoq)
Timing of Vaccination
Risk Assessment for Vaccine Indication
Dosing Schedule
Safety and Contraindications
Practical Pitfalls to Avoid
Strength of evidence: Not explicitly graded in the cited MMWR Recommendations and Reports; recommendations are based on expert consensus and epidemiologic data.